11/12
09:13 am
immx
Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch [Yahoo! Finance]
High
Report
Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch [Yahoo! Finance]
11/12
09:00 am
immx
Immix Biopharma appoints Michael Grabow as chief commercial officer to drive NXC-201 launch [Seeking Alpha]
High
Report
Immix Biopharma appoints Michael Grabow as chief commercial officer to drive NXC-201 launch [Seeking Alpha]
11/12
08:45 am
immx
Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch
High
Report
Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch
11/3
08:45 am
immx
Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025
Medium
Report
Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025
10/14
08:45 am
immx
Immix Biopharma to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference
Low
Report
Immix Biopharma to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference
10/8
12:25 pm
immx
Immix Biopharma (NASDAQ:IMMX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Immix Biopharma (NASDAQ:IMMX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
10/6
04:47 pm
immx
Immix Biopharma to Present Abstract at the upcoming ASH 2025 Annual Meeting [Yahoo! Finance]
High
Report
Immix Biopharma to Present Abstract at the upcoming ASH 2025 Annual Meeting [Yahoo! Finance]
10/6
04:05 pm
immx
Immix Biopharma to Present Abstract at the upcoming ASH 2025 Annual Meeting
High
Report
Immix Biopharma to Present Abstract at the upcoming ASH 2025 Annual Meeting
10/1
08:45 am
immx
Immix Biopharma to Present at the 37th Annual Piper Sandler Healthcare Conference
Low
Report
Immix Biopharma to Present at the 37th Annual Piper Sandler Healthcare Conference
9/18
01:30 pm
immx
Immix Biopharma Announces 50% Enrollment Milestone Surpassed in its ongoing relapsed/refractory AL Amyloidosis Clinical Trial, NEXICART-2
Neutral
Report
Immix Biopharma Announces 50% Enrollment Milestone Surpassed in its ongoing relapsed/refractory AL Amyloidosis Clinical Trial, NEXICART-2
9/12
08:03 am
immx
Immix Biopharma (NASDAQ:IMMX) had its price target raised by analysts at HC Wainwright from $7.00 to $8.00. They now have a "buy" rating on the stock.
Medium
Report
Immix Biopharma (NASDAQ:IMMX) had its price target raised by analysts at HC Wainwright from $7.00 to $8.00. They now have a "buy" rating on the stock.
9/11
09:41 am
immx
Nancy T. Chang, Proven Biotechnology Leader, Joins Immix Biopharma Board of Directors [Yahoo! Finance]
Low
Report
Nancy T. Chang, Proven Biotechnology Leader, Joins Immix Biopharma Board of Directors [Yahoo! Finance]
9/11
09:15 am
immx
Nancy T. Chang, Proven Biotechnology Leader, Joins Immix Biopharma Board of Directors
Low
Report
Nancy T. Chang, Proven Biotechnology Leader, Joins Immix Biopharma Board of Directors
9/8
04:32 pm
immx
Immix Biopharma Announces Strategic Investment by Houston based Goose Capital, led by founding member Dr. Nancy T. Chang [Yahoo! Finance]
Medium
Report
Immix Biopharma Announces Strategic Investment by Houston based Goose Capital, led by founding member Dr. Nancy T. Chang [Yahoo! Finance]
9/8
04:05 pm
immx
Immix Biopharma Announces Strategic Investment by Houston based Goose Capital, led by founding member Dr. Nancy T. Chang
Medium
Report
Immix Biopharma Announces Strategic Investment by Houston based Goose Capital, led by founding member Dr. Nancy T. Chang